Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: An equilibrium contrast cardiovascular magnetic resonance study

Circulation: Cardiovascular Imaging

Volumn 6, Issue 1, 2013, Pages 34-39

  Banypersad, Sanjay M ^a,b,c   Sado, Daniel M ^a,c   Flett, Andrew S ^a   Gibbs, Simon D J ^b   Pinney, Jennifer H ^b   Maestrini, Viviana ^a   Cox, Andrew T ^a   Fontana, Marianna ^a,b   Whelan, Carol J ^a,b   Wechalekar, Ashutosh D ^b   Hawkins, Philip N ^b   Moon, James C ^a,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloid; Cardiac; Cardiac MRI; Cardiomyopathy; Heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; GADOTERATE MEGLUMINE; TROPONIN T; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CONVENTIONAL ANGIOGRAPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXTRACELLULAR SPACE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WALKING; DIFFERENTIAL DIAGNOSIS; DOPPLER ECHOCARDIOGRAPHY; EXTRACELLULAR FLUID; FOLLOW UP; HEART DISEASE; HEART MUSCLE; HEART STROKE VOLUME; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PRIMARY AMYLOIDOSIS; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY;

AGED; AMYLOID; AMYLOIDOSIS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY, DOPPLER; EXTRACELLULAR FLUID; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HEART DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; STROKE VOLUME;

MLCS; MLOWN;

EID: 84874533688     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.112.978627     Document Type: Article

References (23)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
2. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Bux-baum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336:466-473.
3. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac tropo-nins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881-1887.
4. Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A, Zeldis JB, Sancho-rawala V. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood. 2010;116:5071-5072.
5. Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysi-ologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046-1051.
6. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon A P, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93-97.
7. Minutoli F, Gaeta M, Di Bella G, Crisafulli C, Militano V, Brancati M, Di Leo R, Mazzeo A, Baldari S. Cardiac Involvement in Transthyretin Familial Amyloid Polyneuropathy-comparison between 99mTc-DPD SPECT and magnetic resonance imaging. European Association of Nuclear Medicine. European Association of Nuclear Medicine. 2010;37(Suppl 2):S382.
8. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Shep-pard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-193.
9. White SK, Sado DM, Flett AS, Moon JC. Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart. 2012;98:773-779.
10. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fbrosis: preliminary validation in humans. Circulation. 2010;122:138-144.
11. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49:9-13.
12. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Defnition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10#sup#th#/sup# International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319-328.
13. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal probrain natriuretic peptide: a staging system for primary systemic amyloido-sis. J Clin Oncol. 2004;22:3751-3757.
14. Monia BP AE, Guo S, Benson MD. Clinical Development of an antisensse therapy for the treatment of TTR-associated polyneuropathy. 8th International Symposium on Familial Amyloid polyneuropathy. 2011;S2-S8.
15. Sado D, Flett A, White S, Banypersad SM, Maestrini V, Mehta A, Hawkins PN, Hausenloy DJ, Elliott P, Moon JC. Interstitial expansion in health and disease-an equilibrium contrast CMR study. Abstracts of the 15th Annual SCMR Scientifc Sessions. J Cardiovasc Magn Reson. 2012;14(suppl 1):1.
16. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L, Merlini G. Treatment with oral melphalan plus dexamethasone produces longterm remissions in AL amyloidosis. Blood. 2007;110:787-788.
17. Cheng ZW, Tian Z, Kang L, Chen TB, Fang LG, Cheng KA, Zeng Y, Fang Q. [Electrocardiographic and echocardiographic features of patients with primary cardiac amyloidosis]. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38:606-609.
18. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Elec-trocardiographic fndings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95:535-537.
19. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chan-drasekaran K, McConnell JP, Burritt MF, Jaffe AS. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787-1789.
20. Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol. 1983;52:137-146.
21. Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modifed look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging. 2007;26:1081-1086.
22. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD. Shortened Modifed Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69.
23. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen MY, Bandettini WP, Arai AE. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012;33:1268-1278.